title: Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis.
abstract: BACKGROUND
  The prevalence of obsessive-compulsive symptoms (OCS) in patients with schizophrenia is relatively high. Antipsychotics have been found to influence OCS.
  
  
  OBJECTIVE
  To determine whether induction or severity of OCS differs during treatment with olanzapine or risperidone in young patients with early psychosis.
  
  
  METHODS
  One hundred twenty-two patients with a Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder were randomized in a double-blind design to groups of 6 weeks' treatment with olanzapine (n = 59) or risperidone (n = 63), with a mean dose of 11.3 mg olanzapine and 3.0 mg risperidone at 6 weeks. Primary outcome measures were the mean baseline-to-endpoint change in total score on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS).
  
  
  RESULTS
  Treatment with olanzapine was associated with greater decreases in Y-BOCS total score than treatment with risperidone in total group (N = 122: -2.2 vs -0.3, z = -2.651, P < 0.01), in patients with baseline Y-BOCS total score greater than 0 (n = 58: -5.1 vs -0.4, z = -2.717, P < 0.01), and in patients with baseline Y-BOCS total score greater than 10 (n = 29: -7.1 vs -0.6, z = -2.138, P = 0.032).
  
  
  CONCLUSIONS
  In this randomized, 6-week, double-blind trial, we found a significant and clinically relevant difference in decrease in Y-BOCS scores favoring olanzapine compared with risperidone.
authors.affiliation: Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. l.vannimwegen@erasmusmc.nl
authors.forename: Lonneke
authors.initials: L
authors.lastname: van Nimwegen
authors.forename: Lieuwe
authors.initials: L
authors.lastname: de Haan
authors.forename: Nico
authors.initials: N
authors.lastname: van Beveren
authors.forename: Winfried
authors.initials: W
authors.lastname: Laan
authors.forename: Wim
authors.initials: W
authors.lastname: van den Brink
authors.forename: Don
authors.initials: D
authors.lastname: Linszen
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use*; D002214:Capsules; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000209:etiology; D000077152:Olanzapine; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy*; D018967:Risperidone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D002214:Capsules; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine